Holen Sie sich die Stockscreener-App
1.67
0.60%
-0.01
Handel nachbörslich:
1.68
0.01
+0.60%
Schlusskurs vom Vortag:
$1.68
Offen:
$1.66
24-Stunden-Volumen:
277.28K
Relative Volume:
0.83
Marktkapitalisierung:
$22.59M
Einnahmen:
$1.89M
Nettoeinkommen (Verlust:
$-17.92M
KGV:
-0.2496
EPS:
-6.69
Netto-Cashflow:
$-15.62M
1W Leistung:
+13.61%
1M Leistung:
+39.17%
6M Leistung:
-2.91%
1J Leistung:
-46.82%
1-Tages-Spanne:
$1.58
$1.6977
1-Wochen-Bereich:
$1.43
$1.80
52-Wochen-Spanne:
$1.14
$4.29
Longeveron Inc Stock (LGVN) Company Profile
Firmenname
Longeveron Inc
Sektor
Branche
Telefon
305-302-7158
Adresse
1951 NW 7TH AVENUE, MIAMI
Vergleichen Sie LGVN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LGVN
Longeveron Inc
|
1.67 | 22.06M | 1.89M | -17.92M | -15.62M | -6.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Longeveron Inc Stock (LGVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-06 | Eingeleitet | ROTH MKM | Buy |
Longeveron Inc Aktie (LGVN) Neueste Nachrichten
Is Longeveron Inc. a good long term investmentExplosive earnings growth - jammulinksnews.com
Longeveron Inc. Stock Analysis and ForecastPowerful profit generation - jammulinksnews.com
What drives Longeveron Inc. stock priceHigh-impact investment strategies - jammulinksnews.com
What analysts say about Longeveron Inc. stockExceptional profit margins - jammulinksnews.com
Published on: 2025-07-22 07:30:15 - Autocar Professional
Longeveron licenses stem cell patent for heart disease treatment - Investing.com
Longeveron Licenses US Patent for Advanced Cardiomyogenic Cell Technology from University of Miami - Nasdaq
Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease - The Manila Times
Revolutionary Heart Disease Breakthrough: Longeveron Licenses Safer Cardiac Stem Cell Technology - Stock Titan
What makes Longeveron Inc. stock price move sharplyFree Exclusive Stock Market Insights - Newser
Why Longeveron Inc. stock attracts strong analyst attentionLong Term Safe Yield Focus - Newser
How Longeveron Inc. stock performs during market volatilityFree Stock Market Group - Newser
Longeveron (LGVN) gets FDA nod to start Phase 2 laromestrocel trial | PLUG SEC FilingForm 424B7 - Stock Titan
Longeveron receives FDA approval for pediatric heart therapy IND By Investing.com - Investing.com South Africa
Longeveron®? Announces U.S. FDA Approval of IND Application for A Phase 2 Pivotal Registration Study Evaluating Laromestrocel as A Treatment of Pediatric Dilated Cardiomyopathy - MarketScreener
Longeveron® announces U.S. FDA approval of IND application - MarketScreener
Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM) - The Manila Times
Longeveron stock soars after FDA approves IND for heart failure treatment - Investing.com Nigeria
Longeveron stock soars after FDA approves IND for heart failure treatment By Investing.com - Investing.com South Africa
Longeveron Inc. Receives FDA Approval for IND Application to Advance Clinical Trial of Stem Cell Therapy for Pediatric Dilated Cardiomyopathy - Nasdaq
Breakthrough: FDA Fast-Tracks New Stem Cell Therapy for Fatal Children's Heart Condition - Stock Titan
Longeveron (NASDAQ:LGVN) Shares Down 1.5% – What’s Next? - Defense World
Longeveron appoints Than Powell as chief business officer - Investing.com
Longeveron (LGVN) Appoints New Chief Business Officer to Lead Strategic Initiatives | LGVN Stock News - GuruFocus
Longeveron® Appoints Than Powell as Chief Business Officer - GlobeNewswire
Longeveron appoints Than Powell as chief business officer By Investing.com - Investing.com UK
Longeveron completes enrollment in HLHS pediatric heart trial - Investing.com India
Longeveron completes enrollment in HLHS pediatric heart trial By Investing.com - Investing.com Nigeria
Alzheimer's & Brain Awareness Month 2025: Looking Back at Recent Progress in Cell and Gene Therapy - CGTLive®
Transcript : Longeveron Inc.Shareholder/Analyst Call - MarketScreener
Jane Street Group LLC Acquires New Shares in Longeveron Inc. (NASDAQ:LGVN) - Defense World
Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference - The Manila Times
Longeveron Inc. CEO Wa’el Hashad to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference - Nasdaq
Finanzdaten der Longeveron Inc-Aktie (LGVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):